Patient Care Prioritized.

WHERE IT MATTERS MOST

The new normal in healthcare is yet to be defined, but there are practical steps that can help get Back2Care. Speed digital transformation and ensure your financial health as you address the backlog of care with both agility and precision.
  • Prioritize Patient Procedures with AI-powered Precision
  • Deliver Focused Interventions and Re-engage Populations
  • Empower the Human Side of Care with Digital Transformation

That’s where EarlySign can help.

First and foremost, by using routine data to identify and prioritize those patients potentially at high risk who will benefit from accelerated attention, we can help you honor the resilience of your team by enabling them to focus on delivering care that matters right now.

With bundles focused on clinical domains, prioritization, readmissions, and adherence models, we offer extensive opportunities to aid in early detection and prevention of high burden disease.

New—COVID-19 Complications AlgoMarker

Available now!

AlgoMarkers™

Each AlgoMarker™ is a condition-specific clinical predictor used by healthcare organizations to identify patients at high-risk for developing or harboring high burden disease. AlgoMarkers™ analyze routine, available lab results and clinical data to provide personalized health trajectory insights.

AlgoAnalyzer™

AlgoAnalyzer™ is a server-side software platform for running various healthcare calculators, including patient-specific algorithmic and predictive models called AlgoMarkers™ AlgoAnalyzer™ is designed to integrate easily into clinical laboratory (LIS) and population health management IT ecosystems and workflows.

Who we help

solutions for

Identify patients on high-risk trajectories, helping providers prevent or delay disease progression.

solutions for

Enable value-based transformation of laboratory medicine with patient-specific insights and risk stratification. This helps physicians, providers and payors find opportunities to efficiently deliver care.

solutions for

Flag eligible populations for clinical trials, identify cohorts for therapeutic efforts, and work with clinical partners.

Are you looking to solve high-burden disease challenges?